Jenny McCue is Executive Director of Patient Advocacy at Ultragenyx where she leads the team in developing treatments for rare and ultra-rare pediatric neurological and bone diseases. She has dedicated her personal and professional life to ensuring patients, especially in the areas of rare and maternal and fetal disease, are part of the treatment discovery and development process.
She has over 15 years of extensive experience holding leadership positions in all sectors involved in drug development; advocacy organizations, federal government, large pharmaceutical companies and biotech space. It is her hands on knowledge of how all the players work that makes her an expert in bringing the patient voice throughout every phase of the drug development process.
Prior to Ultragenyx, Jenny served as Head of Patient Advocacy and Engagement at Momenta Pharma where she developed and deployed a global advocacy strategy across multiple rare immune mediated diseases and led collaboration with a cross functional team. Specifically, her work in Hemolytic Disease of the Fetus and Newborn changed her life as it connected her to Bethany. She first met Bethany years ago while building Momenta pharmaceuticals advocacy platform for HDFN and has never stopped believing in the work being done by the Allo Hope Foundation.
Jenny received her Master’s Degree in Health Policy from the University of Chicago. She holds a Masters Degree in Philosophy from Marquette University along with Bachelor’s degree in philosophy and sociology from Marquette University. She spent a fabulous year of her undergraduate career studying philosophy overseas at Oxford University. Jenny and her husband Matt live in Wisconsin with their beloved dog Juno and enjoy spending their time with their community, going on adventures on their farm, and doting on their 13 nieces and nephews scattered across the globe from Hawaii, to Africa, Illinois, Colorado and California.